Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Update on cost-effectiveness of a 12-dose regimen for latent tuberculous infection at new rifapentine prices.

× No keyword cloud information.

8 in total

1. Activism on rifapentine pricing: removing cost barriers to improve the uptake of tuberculosis research innovations.

Authors: A DeLuca; M Frick; E Lessem; J Kanouse; D Wegener; L Ruiz Mingote
Journal: Public Health Action Date: 2014-12-21

Review 2. Latent tuberculosis infection: the final frontier of tuberculosis elimination in the USA.

Authors: Philip A LoBue; Jonathan H Mermin
Journal: Lancet Infect Dis Date: 2017-05-08 Impact factor: 25.071

3. The Health and Economic Benefits of Tests That Predict Future Progression to Tuberculosis Disease.

Authors: Nicolas A Menzies; Sourya Shrestha; Andrea Parriott; Suzanne M Marks; Andrew N Hill; David W Dowdy; Priya B Shete; Ted Cohen; Joshua A Salomon
Journal: Epidemiology Date: 2022-01-01 Impact factor: 4.822

4. A shorter treatment regimen for latent tuberculosis infection holds promise for at-risk Canadians.

Authors: C Pease; K R Amaratunga; G G Alvarez
Journal: Can Commun Dis Rep Date: 2017-03-02

5. Impacts of 12-dose regimen for latent tuberculosis infection: Treatment completion rate and cost-effectiveness in Taiwan.

Authors: Yi-Wen Huang; Shun-Fa Yang; Yen-Po Yeh; Thomas Chang-Yao Tsao; Shih-Ming Tsao
Journal: Medicine (Baltimore) Date: 2016-08 Impact factor: 1.889

6. Treatment completion for latent tuberculosis infection: a retrospective cohort study comparing 9 months of isoniazid, 4 months of rifampin and 3 months of isoniazid and rifapentine.

Authors: Adelaide H McClintock; McKenna Eastment; Christy M McKinney; Caroline L Pitney; Masahiro Narita; David R Park; Shireesha Dhanireddy; Alexandra Molnar
Journal: BMC Infect Dis Date: 2017-02-14 Impact factor: 3.090

7. Treatment of latent Mycobacterium tuberculosis infection with 12 once weekly directly-observed doses of isoniazid and rifapentine among persons experiencing homelessness.

Authors: Nwabunie Nwana; Suzanne M Marks; Edward Lan; Alicia H Chang; Michael Holcombe; Sapna Bamrah Morris
Journal: PLoS One Date: 2019-03-13 Impact factor: 3.240

8. Treatment shortening of drug-sensitive pulmonary tuberculosis using high-dose rifampicin for 3 months after culture conversion (Hi-DoRi-3): a study protocol for an open-label randomized clinical trial.

Authors: Nakwon Kwak; Doosoo Jeon; Youngmok Park; Young Ae Kang; Kyung Jong Kim; Young Ran Kim; Byoung Soo Kwon; Yong-Soo Kwon; Hyung-Jun Kim; Jae Ho Lee; Ji Yeon Lee; Jung-Kyu Lee; Jeongha Mok; Minkyoung Cheon; Jiwon Park; Seokyung Hahn; Jae-Joon Yim
Journal: Trials Date: 2022-08-17 Impact factor: 2.728

8 in total